CAS 13718-26-8|Sodium metavanadate

CHEMICAL IDENTIFICATION

RTECS NUMBER :

YW1050000

CHEMICAL NAME :

Vanadic acid, monosodium salt

CAS REGISTRY NUMBER :

13718-26-8

LAST UPDATED :

199710

DATA ITEMS CITED :

45

MOLECULAR FORMULA :

O3-V.Na

MOLECULAR WEIGHT :

121.93

WISWESSER LINE NOTATION :

NA VA-O3

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Rodent - rat

DOSE/DURATION :

98 mg/kg

TOXIC EFFECTS :

Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea Gastrointestinal - hypermotility, diarrhea

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Intraperitoneal

SPECIES OBSERVED :

Rodent - rat

DOSE/DURATION :

12 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Rodent - mouse

DOSE/DURATION :

74600 ug/kg

TOXIC EFFECTS :

Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea Gastrointestinal - hypermotility, diarrhea

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Intraperitoneal

SPECIES OBSERVED :

Rodent - mouse

DOSE/DURATION :

36 mg/kg

TOXIC EFFECTS :

Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea Gastrointestinal - hypermotility, diarrhea

TYPE OF TEST :

LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :

Subcutaneous

SPECIES OBSERVED :

Mammal - dog

DOSE/DURATION :

17 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :

LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :

Intravenous

SPECIES OBSERVED :

Mammal - dog

DOSE/DURATION :

11 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Intravenous

SPECIES OBSERVED :

Mammal - cat

DOSE/DURATION :

7180 ug/kg

TOXIC EFFECTS :

Vascular - BP elevation not characterized in autonomic section Vascular - BP lowering not characterized in autonomic section

TYPE OF TEST :

LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Rodent - rabbit

DOSE/DURATION :

200 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :

LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :

Intravenous

SPECIES OBSERVED :

Rodent - rabbit

DOSE/DURATION :

17 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Rodent - rat

DOSE/DURATION :

25851 ug/kg/6W-I

TOXIC EFFECTS :

Gastrointestinal - malabsorption Kidney, Ureter, Bladder - changes in bladder weight Nutritional and Gross Metabolic - changes in calcium

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Rodent - rat

DOSE/DURATION :

517 mg/kg/12W-I

TOXIC EFFECTS :

Gastrointestinal - other changes Liver - other changes Nutritional and Gross Metabolic - changes in metals, not otherwise specified

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Rodent - rat

DOSE/DURATION :

3878 mg/kg/90D-I

TOXIC EFFECTS :

Cardiac - other changes Endocrine - other changes Biochemical - Neurotransmitters or modulators (putative) - catecholamine levels in CNS

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Rodent - rat

DOSE/DURATION :

718 mg/kg/30W-C

TOXIC EFFECTS :

Cardiac - pulse rate increase, without fall in BP Vascular - BP elevation not characterized in autonomic section Kidney, Ureter, Bladder - other changes in urine composition

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Intraperitoneal

SPECIES OBSERVED :

Rodent - rat

DOSE/DURATION :

25 mg/kg/5D-I

TOXIC EFFECTS :

Brain and Coverings - other degenerative changes

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Intraperitoneal

SPECIES OBSERVED :

Rodent - rat

DOSE/DURATION :

17500 ug/kg/10W-I

TOXIC EFFECTS :

Behavioral - changes in motor activity (specific assay) Gastrointestinal - decreased motility or constipation

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Oral

DOSE :

1800 mg/kg

SEX/DURATION :

male 30 day(s) pre-mating

TOXIC EFFECTS :

Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Fertility - male fertility index (e.g. # males impregnating females per # males exposed to fertile nonpregnant females)

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Intraperitoneal

DOSE :

25 mg/kg

SEX/DURATION :

female 9 day(s) after conception

TOXIC EFFECTS :

Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Intraperitoneal

DOSE :

25 mg/kg

SEX/DURATION :

female 12 day(s) after conception

TOXIC EFFECTS :

Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Intraperitoneal

DOSE :

40 mg/kg

SEX/DURATION :

female 6-15 day(s) after conception

TOXIC EFFECTS :

Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Intraperitoneal

DOSE :

80 mg/kg

SEX/DURATION :

female 6-15 day(s) after conception

TOXIC EFFECTS :

Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

MUTATION DATA

TYPE OF TEST :

Sex chromosome loss and nondisjunction

TEST SYSTEM :

Human Lymphocyte

REFERENCE :

MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 319,205,1993 *** REVIEWS *** TOXICOLOGY REVIEW FRMBAZ Farmacia (Bucharest). (Rompresfilatelia, POB 12-201, Bucharest, Romania) V.1- 1953- Volume(issue)/page/year: 21,325,1973 TOXICOLOGY REVIEW 85DHAX "Medical and Biologic Effects of Environmental Pollutants Series," Washington, DC, National Academy of Sciences, 1972-77 Volume(issue)/page/year: V,46,1974 *** OCCUPATIONAL EXPOSURE LIMITS *** OEL-AUSTRALIA:TWA 0.05 mg(V2O5)/m3 JAN 1993 OEL-BELGIUM:TWA 0.05 mg(V2O5)/m3 JAN 1993 OEL-DENMARK:TWA 0.03 mg(V2O5)/m3 JAN 1993 OEL-FINLAND:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-FRANCE:TWA 0.05 mg(V2O5)/m3 JAN 1993 OEL-GERMANY:TWA 0.05 mg(V2O5)/m3 JAN 1993 OEL-HUNGARY:TWA 0.05 mg(V2O5)/m3;STEL 0.1 mg(V205)/m3 JAN 1993 OEL-JAPAN:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-THE NETHERLANDS:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-THE PHILIPPINES:TWA 0.25 mg(V205)/m3 JAN 1993 OEL-POLAND:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-SWEDEN:STEL 0.05 mg(V2O5)/m3 JAN 1993 OEL-SWEDEN:TWA 0.2 mg(V2O5)/m3 (dust) JAN 1993 OEL-SWITZERLAND:TWA 0.05 mg(V2O5)/m3;STEL 0.25 mg(V2O5)/m3 JAN 1993 OEL-TURKEY:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-UNITED KINGDOM:TWA 0.05 mg(V2O5)/m3 (dust) JAN 1993 OEL-UNITED KINGDOM:TWA 0.5 mg(V2O5)/m3 JAN 1993 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH RECOMMENDED EXPOSURE LEVEL (REL) : NIOSH REL TO VANADIUM (as V2O5), resp dust/fume-air:CL 0.05 mg/m3/15M REFERENCE : NIOSH* National Institute for Occupational Safety and Health, U.S. Dept. of Health, Education, and Welfare, Reports and Memoranda. Volume(issue)/page/year: DHHS #92-100,1992

Behav. Brain Res. 282 , 125-32, (2015)

Attention deficit hyperactivity disorder (ADHD) overdiagnosis and a pharmacological attempt to increase cognitive performance, are the major causes for the frequent (ab)use of psychostimulants in non-...

J. Neurosci. 35(3) , 972-84, (2015)

Although the MAP kinase-interacting kinases (MNKs) have been known for >15 years, their roles in the regulation of protein synthesis have remained obscure. Here, we explore the involvement of the MNKs...

PLoS ONE 10 , e0129217, (2015)

Previous studies on the degenerative animal model of multiple sclerosis suggested that the copper-chelator cuprizone might directly suppress T-cell functions. Peripheral T-cell function in the cuprizo...